ArticleFrontiers in immunology2025
Serum proteomics and machine learning identify PSMD11 as a prognostic biomarker in severe fever with thrombocytopenia syndrome.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Explainable Machine Learning Model for Early Prediction of Incident Myocardial Injury in Patients With Severe Fever With Thrombocytopenia Syndrome.Journal of medical virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne viral disease associated with high mortality. This study aimed to characterize serum proteomic signatures linked to adverse outcomes and to identify prognostic biomarkers with potential translational value for patient management. Methods: Serum samples from 55 survivors, 32 non-survivors, and 10 healthy controls were analyzed by data-independent acquisition-based proteomics. Differential abundance analysis, Gene Ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and protein-protein interaction (PPI) network analyses with Markov clustering were conducted to characterize disease-associated proteins. XGBoost and Random Forest machine learning models were applied to prioritize candidate biomarkers, and discriminative performance was evaluated by the receiver operating characteristic (ROC) curve. Spearman correlation analyses were further used to examine associations between candidate proteins, clinical laboratory indicators, and viral load. Results: Non-survivors exhibited 642 differentially abundant proteins (DAPs) compared with survivors. Functional enrichment and PPI network analyses revealed a proteasome-centered module overrepresented in non-survivors. XGBoost and Random Forest consistently prioritized four candidate biomarkers (PSMD11, IL1RL1, PSMC4, and IFIH1) with areas under the ROC curve of 0.847, 0.847, 0.843, and 0.791, respectively. PSMD11 emerged as the strongest predictor of adverse outcome and showed strong correlations with markers of organ injury and dysfunction such as lactate dehydrogenase ( Conclusions: This study identified a proteasome-centered signature associated with adverse outcomes in SFTS, with PSMD11 emerging as a key prognostic biomarker. Its strong correlations with viral load and multi-organ injury support potential utility for early risk stratification and prognostic prediction, while also providing mechanistic insights into disease progression and a foundation for future translational research and therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.